Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.82 |
| ▸ | ITGAV | P06756 | 20/20 | 0.82 |
| ▸ | ITGB6 | P18564 | 19/20 | 0.82 |
| ▸ | ITGB5 | P18084 | 12/20 | 0.82 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.63 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840996 | 0.95 | ITGB3 (0.82) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL6265063 | 0.91 | ITGB3 (0.68) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL2836956 | 0.90 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL2833650 | 0.87 | ITGB3 (0.84) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL8326227 | 0.86 | ITGB3 (0.68) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL2837995 | 0.85 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL2838535 | 0.84 | ITGB3 (0.84) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL6267787 | 0.81 | ITGB3 (0.83) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL2842256 | 0.81 | ITGB3 (0.82) | ITGB3ITGAVITGB6ITGB5ITGA2B | |
| SCHEMBL2841229 | 0.81 | ITGB3 (0.55) | ITGB3ITGAVITGB6ITGB5ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592421-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2005-11-09 | — | — | EP | claimed |
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | claimed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | claimed |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-9345739-B2 | Methods and compositions for the treatment of proteinuric diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2730282-A1 | Methods and compositions for the treatment of proteinuric diseases | The General Hospital Corporation (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2009061448-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| EP-1592421-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGAV, ITGA6 | ITGB3 6/4885ITGAV 2/4885ITGB6 5/4885 |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | ITGB3 1/4885ITGAV 16/4885ITGB6 23/4885 |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | ITGB3 1/4885ITGAV 16/4885ITGB6 23/4885 |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | ITGB3, PLAUR, PROC | ITGB3 1/4885ITGAV 16/4885ITGB6 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.